Tango Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Tango Therapeutics sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Tango Therapeutics: 6 sponsored US clinical trials, 4 recruiting.
Tango Therapeutics sponsors 6 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Lung Cancer, with 3 trials.
Upper-quartile sponsor footprint
Tango Therapeutics sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
NCT06922591
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
NCT06810544
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT05887492
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors
NCT05732831
Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors
NCT05275478
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
NCT06065059
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 6 |
What is open in the Tango Therapeutics pipeline
4 recruiting of 6 indexed (67% open).
Phase mix: 0 late (III/IV) vs 6 early (I/II) (early-phase heavy).
Top condition: Lung Cancer (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Tango Therapeutics: open-pipeline peers nationwide
Peers matched on 6 registered trials and 67% open enrollment, not the therapeutic-area sidebar.
Tango Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 67% open enrollment (± trial volume)
- ABL Bio · 67% recruiting · 3 trials
- Accelerated Cure Project for Multiple Sclerosis · 67% recruiting · 3 trials
- Advanced Reconstructive Surgery Alliance · 67% recruiting · 3 trials
- Alexander B Olawaiye, MD · 67% recruiting · 3 trials
Related
What to do with this Tango Therapeutics page
6 registered trials is a research-attention snapshot, not an endorsement of Tango Therapeutics or any single study.
- 4 of Tango Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Lung Cancer is the condition Tango Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Lung Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Tango Therapeutics pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.